# GSK BHR Study (Sont - Second Study)

> **NCT01324362** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 446 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** FP 100mcg
- **DRUG:** FP 250mcg
- **DRUG:** FP 500mcg
- **DRUG:** FSC 100/50mcg
- **DRUG:** FSC 250/50mcg
- **DRUG:** FSC500/50mcg

## Key facts

- **NCT ID:** NCT01324362
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2016-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324362, "GSK BHR Study (Sont - Second Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01324362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*